Soligenix Inc. announced that new supportive trial data for HyBryte in the treatment of cutaneous T-cell lymphoma will be presented at the United States Cutaneous Lymphoma Consortium Workshop on March 26, 2026, ahead of the American Academy of Dermatology Annual Meeting. The presentations will highlight positive results from a long-term treatment study and a comparative analysis versus Valchlor, supporting HyBryte's potential as a therapeutic option for CTCL.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company's Specialized BioTherapeutics business segment is developing HyBryte as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.
The development programs in this business segment also include expansion of synthetic hypericin into psoriasis, first-in-class innate defense regulator technology for inflammatory diseases including oral mucositis in head and neck cancer, and treatments for Behcet's Disease. The company's Public Health Solutions business segment includes development programs for vaccine candidates targeting ricin toxin, filoviruses such as Marburg and Ebola, and COVID-19 prevention, incorporating proprietary heat stabilization platform technology known as ThermoVax.
This business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency and the Biomedical Advanced Research and Development Authority. The latest news and updates relating to Soligenix are available in the company's newsroom at https://ibn.fm/SNGX.
For business and technology leaders in the healthcare sector, the presentation of new HyBryte data represents significant progress in addressing unmet medical needs in rare diseases. The comparative analysis against Valchlor provides valuable insights for treatment decision-making in cutaneous T-cell lymphoma, while the long-term study data offers important safety and efficacy information for potential regulatory submissions. The company's dual focus on specialized biotherapeutics and public health solutions demonstrates a strategic approach to addressing both niche medical markets and broader public health challenges.
The timing of this presentation ahead of the American Academy of Dermatology Annual Meeting positions the data for maximum visibility within the dermatology community. For investors and industry observers, the progression of HyBryte through clinical development toward potential commercialization represents a milestone in bringing novel photodynamic therapy to market. The company's utilization of government funding for public health initiatives also highlights the growing intersection between private biotechnology development and public health infrastructure.
